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Abstract
Dietary impacts on health may be one of the oldest concepts in medicine; however, only in recent
years have technical advances in mass spectroscopy, gnotobiology, and bacterial sequencing
enabled our understanding of human physiology to progress to the point where we can begin to
understand how individual dietary components can affect specific illnesses. This review explores
the current understanding of the complex interplay between dietary factors and the host
microbiome, concentrating on the downstream implications on host immune function and the
pathogenesis of disease. We discuss the influence of the gut microbiome on body habitus and
explore the primary and secondary effects of diet on enteric microbial community structure. We
address the impact of consumption of non-digestible polysaccharides (prebiotics and fiber),
choline, carnitine, iron, and fats on host health as mediated by the enteric microbiome. Disease
processes emphasized include nonalcoholic fatty liver disease (NAFLD)/non-alcoholic
steatohepatitis (NASH), IBD, and cardiovascular disease (CVD)/atherosclerosis. The concepts
presented in this review have important clinical implications, although more work needs to be
done to fully develop and validate potential therapeutic approaches. Specific dietary interventions
offer exciting potential for nontoxic, physiologic ways to alter enteric microbial structure and
metabolism to benefit the natural history of many intestinal and systemic disorders.
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Diet has long been considered a primary factor in health; however, with the microbiome
revolution of the past decade, we have begun to understand how diet can alter the microbial
composition and function of a given host.[1] An appreciation of the role of the host
microbial community in mucosal homeostasis and a variety of diseases has developed
alongside our understanding of the complexities of the microbiome-host interaction.
Perhaps the best example of the microbiome-host interaction in a disease state is in the
pathogenesis of inflammatory bowel diseases (IBD), which is believed to be the result of an
imbalanced reaction between the genetically regulated host immune system and the
microbiome, with important environmental influences.[2] Recent advances suggest that the
genetic background of the host may influence the host’s microbiome, with a downstream
impact on an individual’s susceptibility to develop IBD, and the severity of their disease.[3]
In particular, the rise of IBD incidence in Asia as diet and lifestyle have become more
Westernized[4] demonstrates the profound effects that the microbiome can have on a
patient’s health. Similarly, metagenomic/metaproteomic studies have found that ileal
Crohn’s disease (CD) patients have a unique signature in both bacterial and host expression
profiles.[5]
This review explores the current understanding of interplay between dietary factors and the
host microbiome, concentrating on the downstream implications on host immune function
and the pathogenesis of disease. In some of these examples, the interplay between all of
these various components has not been established. In others, the kinetics of microbial
community shifts need further mechanistic exploration to determine whether the change in
microbial status is pathogenic, supportive of pathology, or merely a downstream result of a
disease stated.
This review is divided largely along the lines of the dietary factor being considered; we
cover the role of diet on the microbiome and host health as it relates to the consumption of
non-digestible polysaccharides (fiber and prebiotics), choline, carnitine, iron, and fats.
Disease processes covered include non-alcoholic fatty liver disease (NAFLD)/non-alcoholic
steatohepatitis (NASH), IBD, and cardiovascular disease (CVD)/atherosclerosis. More
generally, we also cover the influence of the microbiome on body habitus and explore newly
developed concepts of enteric microbial community structure, metagenomics, and metabolic
activities. Finally, we provide some general information (Table 1) of our current
understanding of diet and the role in human gastrointestinal health—summarizing both the
topics covered in this review and more general advances in the field, independent of
microbial involvement.
Diet, global microbial communities, and body habitus
Recently, the concept of enterotypes has developed as a means to categorize the
microbiomes of large populations of humans. In a study of the fecal metagenomes of
individuals from 4 countries across multiple continents, it was proposed that the microbial
community structure and molecular functions of a population could be clustered into three
distinct categories, or enterotypes.[6] Interestingly, the phylogenic profile of an enterotype
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was a poor predictor of host physiology, such as body mass index (BMI); however, various
genes and functional (metabolic) modules do correlate with host physiology properties such
as age and BMI.[6] Subsequent studies have questioned the presence of three broad
enterotypes, but the concept of different enteric profiles in human populations is established.
[7]
How a given microbial community responds to diet, the role of host genetics in supporting
microbial community development, and the effects of different bacterial populations and
metabolites on a host’s health all still remain to be determined, but the concept of
functionally distinct microbial communities in human populations has presented a
conceptual focus as the questions are explored.[1] Based on the diet of individuals, Wu et al.
found that normal subjects could be divided into two communities using the same
classification as Arumugam et al.[6]: a Bacteroides dominated profile associated with a high
saturated fat/animal protein diet, and a Prevotella predominant group associated with low
amounts of saturated fats and animal proteins but a high amount of carbohydrates and
simple sugars.[8] This study also found that the Bacteroides enterotype was resistant to
switching to a Prevotella profile during a 10- day feeding trial of a low-fat/high-fiber diet,
suggesting that only long-term dietary changes are able to influence enteric bacterial
community structure.[8]
A study looking at global bacterial populations in vegans, vegetarians, and control subjects
found that vegans had decreased levels of Bacteroides spp., Bifidobacterium spp.,
Escherichia coli, and Enterobacteriaceae spp. compared to control patients, with vegans
serving as an intermediate population.[9] Another study reported that short-term (5-day)
diets stratified into animal-based verses plant-based influenced host microbial composition.
Animal-based diets increased the abundance of bile-tolerant organisms such as Alistipes,
Bilophila, and Bacteroides, and decreased the level of Firmicutes that metabolize dietary
plant polysaccharides such as Roseburia, Eubacterium rectale, and Ruminoccus bromii.[10]
Interestingly, shifting to a plant-based diet had little effect on microbial composition over
this time frame.[10] However, gnotobiotic murine studies demonstrate very rapid shifts in
bacterial gene expression following dietary manipulation.[11]
Given the interplay between diet and the host microbiome, the role of the microbiome in
obesity has not surprisingly been actively explored in recent years.[12] Studies in mice[13]
and humans[14] have found that an obese state is marked by shifts in the microbiome,
specifically a decrease in bacterial diversity with a marked decrease in the abundance of
Bacteroidetes and an increased abundance in either Actinobacteria[14] or Firmicutes[13];
lean subjects were found to have the opposite trend. Study of carbohydrate metabolic
profiles in the human subjects showed clustering along the same Bacteroidetes and
Actinobacteria/Firmicutes profiles as was seen with obesity; subjects with high levels of
Bacteroidetes were enriched in bacterial carbohydrate metabolism enzymes, while subjects
with high level of Firmicutes demonstrated enrichment in transport systems.[14] This study
also demonstrated that while a core microbiome consistent between all subjects (obese and
lean) was not present, a core set of metabolic functions in the microbiome could be
identified.[14] Interestingly, some of this work in part contradicts later studies that
demonstrate that a high fat/protein diet was associated with increased levels of the
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Bacteroides (a genus of the Bacteroidetes phylum); however, this later study looked at diet,
and not end phenotype (lean vs obese body habitus).[8]
Beyond association studies, functional studies in mice have led to some understanding of
how the microbiome can shape body habitus. Germ-free (sterile) mice were found to be
resistant to obesity when fed a high-fat diet, mediated by elevated levels of fasting-induced
adipose factor (Fiaf) induction of peroxisomal proliferator-activated receptor coactivator
(Pgc-1alpha) and increased AMP-activated kinase (AMPK) activity.[7] Additionally, the
microbiota of ob/ob mice were found to have an increased capacity to harvest energy from
the diet. This property was transferable; germ-free lean mice gavaged with an obese-mouse
microbiota developed increased total body fat compared to mice colonized with lean-mouse
microbiota.[15]
Follow-up studies in non-obese and obese Danish individuals confirmed that obese
individuals had decreased levels of microbial diversity, but this population had increased
levels of the Bacteroidetes phylum.[16] This study also explored genetic diversity of the
microbiome as the independent variable, instead of BMI. It was found that independent of
weight/BMI, individuals with low bacterial genetic diversity were found to have higher
levels of insulin resistance, higher levels of serum triglycerides, cholesterol, and insulin, as
well as elevated inflammatory markers (hsCRP and WBC).[16] Additionally, low bacterial
genetic diversity individuals had a shift in microbiota favoring an increase in inflammatory
microbe profiles and a decrease in anti-inflammatory microbes such as F. prausnitzii[17];
even more interestingly, low bacterial-genetic diversity individuals experienced increased
weight/BMI gain compared to high diversity individuals, even after controlling for baseline
BMI/weight.[16] This difference in weight gain was associated with decreased levels of
eight species of bacteria, all but one of which lacked species-specific taxonomic assignment,
but all of which were identified as butyrate producers. This work for the first time suggests
that specific bacterial species could predispose the individual to weight gain, and that
differences in the microbiome and bacterial metabolome of obese individuals might be
involved in the pathogenesis of obesity, rather than being a consequence of it.
Dietary components also regulate bacterial gene transcription, with bacteria responding to
most optimally use the available nutrients. In particular, when gnotobiotic mice were
monoassociated with the human organism Bacteroides thetaiotaomicron, this microbe was
found to differently express genes involved in glycan metabolism in response to either a
polysaccharide-rich or simple-sugar diet to most efficiently use the energy source available
to them.[18] For example, the simple sugar diet up-regulated glycoside hydrolase, as well as
enzymes able to digest host mucus.[18] Mechanistic studies found that α-mannosides
induced the hybrid two-component system BT3172, an environmental sensor that also served
as a molecular scaffold for the glycolysis enzymes glucose-6-phosphate isomerase and
dehydrogenase [19] providing a mechanistic example for a how a dietary component can
regulate bacterial metabolism.
To add to the complexity of the microbiome, in the past decade researchers have begun to
explore how viruses, and in particular bacteriophages, sculpt the microbiome.[20] This work
has largely been limited both by our understanding of the microbiome as a whole, and the
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sequencing and analytical tools available to researchers, which only in recent years have
become powerful enough to explore viral metagenomics.[20] Interestingly, in patients, CD
is associated with higher mucosal bacteriophage counts, suggesting that that the virome may
be involved in the dysbiosis seen in IBD.[21] In the last year, studies of Bacteroidales-like
phage populations in humans have found that like their microbial hosts, these phages can
also be clustered into viral enterotypes,[22] extending the concept of the global microbial
structure to the entire microbial content of the gut.
Non-digestible Polysaccharides (Butyrate Production)
Short-chain fatty acids (SCFAs) are produced by fermentation of non-digestible
carbohydrates by a subset of anaerobic bacteria in the human colon, primarily in the cecum
and proximal colon.[23] Fermentable carbohydrates include pectins, hemicelluloses, gums,
and prebiotic substances including fructose and galactose-oligosaccharides that are not
responsive to mammalian enzymes, but not what we typically think of as dietary fiber, such
as cellulose or wheat bran.[23, 24] The SCFAs produced by fermentation of these dietary
substrates serve as a vital fuel source for the colonic epithelium and key regulators of
immune homeostasis, and serve as the prototypical example of the symbiotic nature between
the microbiome and the host in terms of diet and metabolism.[23] Of the SCFAs, butyrate in
particular is considered to be the preferred fuel of colonocytes.[23, 25]
During intestinal diversions that result from ostomy procedures, patients develop mild
inflammation of the distal, diverted colon, known as diversion colitis. Initial trials in humans
demonstrated that butyrate enemas for 2–6 weeks were able to treat patients with diversion
colitis,[26] suggesting that diversion colitis may be the result of an absence of the
metabolically vital SCFAs. While a follow-up trial f only 2 weeks of treatment did not
recapitulate the results of the initial study[27], more recent studies in rats did replicate the
initial findings[28]. In the treatment of ulcerative colitis (UC), butyrate enemas have showed
some promise in a subset of patients. Most studies have had positive or largely positive
results, with butyrate enemas decreasing rectal inflammation,[29–32] particularly in cases of
5-ASA and steroid-refractory disease.[33] While one randomized, prospective study had
negative results,[34] another had mixed findings, with outcomes trending towards
significance, and suggesting that efficacy was tied to the length of exposure to the butyrate
enema therapy[35]—mirroring the different results seen in the human studies of diversion
colitis.
The mechanisms by which butyrate promotes mucosal health remain to be fully determined.
Besides being an important colonic epithelial fuel source,[25] it also modulates the immune
system in multiple ways. Initial studies using primary human leukocytes found that butyrate
inhibits IL-12 production by S. aureus-stimulated human monocytes.[36] The same study
also found that in anti-CD3 stimulated monocytes, butyrate enhanced IL-10 and IL-4
secretion, but inhibited IL-2 and IFN-γ release,[36] presenting an anti-inflammatory profile
for butyrate. Other in vitro studies have found that butyrate inhibits vascular cell adhesion
molecule (VCAM-1)-mediated leukocyte adhesion to endothelial cells.[37] Ex vivo studies
in mice found that butyrate suppresses colonic immune activation through Fas-mediated
apoptosis of T-cells, including through histone deacetylase (HDAC) 1-dependent Fas
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upregulation.[38] This work also provided evidence that butyrate inhibits IFN-γ mediated
inflammatory signaling, particularly through STAT1 and iNOS, and that loss of butyrate
signaling induces increased expression of inflammatory genes in mice.[38] Other in vitro
findings demonstrate that butyrate inhibits the IFN- γ/STAT1 axis[39], which is important
because enhanced activation of STAT1 occurs in CD patients.[38, 40] Human ex vivo
studies found that butyrate was able to decrease pro-inflammatory cytokine (TNF-β, IL-1β,
IL-6) mRNA expression as well as TNF secretion in intestinal biopsies and peripheral blood
mononuclear cells of CD patients, through inhibition of NF-κB.[41] More recently, studies
in murine bone marrow derived macrophages found that n-butyrate was able to inhibit pro-
inflammatory cytokine signaling through HDAC inhibition, a process independent of toll-
like receptor or G-protein-coupled receptor signaling.[42] This effect has also been observed
in in vitro rectal carcinoma cell culture experiments.[43] Several recent studies
demonstrated that SCFAs augment colonic regulatory T cells (Treg) populations, an action
mediated in part through a SCFA sensing GPCR encoded by the gene Ffar2,[44] and whose
downstream signaling involved decreases in specific histone deacetylases and net increases
in histone acetylation.[44] Arpila and colleagues showed that both butyrate and proprionate,
which share HDAC-modulating activity, but not acetate, promote extrathymic Treg
generation through the intronic enhancer CNSI.[45] This observation is supported by other
work where butyrate directly induced Treg differentiation in the colon and attenuated onset
of experimental colitis.[46] These activities are thought to be mediated through GPM109A
receptors, which jointly bind butyrate and niacin.[47] These observations are highly relevant
to human IBD, since one group of 17 human Clostridium species that produce butyrate and
other SCFA can inhibit experimental colitis.[48]
Based on the role of the microbiome in the production of butyrate, work has also been
undertaken to determine if patients with IBD have a microbiome that predisposes them to
butyrate deficiency. Initial studies found that a subset of patients with IBD had decreased
amounts of the phyla Firmicutes and Bacteroidetes [49], the dominant distal gut phyla and
known butyrate producers.[50, 51] The butyrate-producing Clostridum Group IV taxa/
subphyla was also implicated in IBD dysbiosis.[49] However, this study did not establish if
the microbiome shifts were the result of intestinal inflammation, or were a predisposing
factor helping lead to the IBD state.
The first individual bacterial species of these phylum associated with IBD was found to be
Faecalibacterium prausnitzii, a Firmicutes and member of the Clostridium Group IV.
Patients with recurrent CD after resection were found at the time of resection exam to have
decreased amounts of Faecalibacterium prausnitzii, a butyrate producer, suggesting that
decreased F. prausnitzii may contribute to or be a marker of a dysbiotic state that
predisposes a person to IBD.[17]
Follow-up studies in mice found that oral administration of live F. prausnitzii or its
supernatant was able to ameliorate TNBS-induced colitis in mice, by partially correcting the
dysbiotic state of TNBS-colitis and by inhibiting NF-κB and IL-8 activity.[17] Follow-up
studies have since confirmed that both CD[52] and UC[53] patients have decreased levels of
butyrate producers, in particular Clostridum Group IV members and specifically F.
prausnitzii. In the UC patients, decreased levels of SCFAs (but oddly not butyrate, which
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only had a trend towards a significant decrease with disease) were also seen, but the
decreases observed were not associated with decreases in a specific bacterial species.[53]
Disease activity was inversely correlated with the amount of F. prausnitzii present in the
patients’ stool.[53] R. hominis, another butyrate-producing Firmicutes, was also found to be
decreased in UC patients, with levels inversely correlated with disease activity.[53]
Interestingly, even UC patients in remission had decreased levels of SCFA producers of the
Clostridium Group IV, regardless of geographic region,[54] suggesting that part of host
susceptibility to UC may be a genetic background or dietary factors that diminish
colonization of intestinal track by butyrate producers.
Outside of IBD, there also appears to be an association between decreased levels of butyrate
producers in other diarrheal diseases. C. difficile infection, the most common cause of
antibiotic-associated diarrhea, with over a half million cases of diarrhea in the United States
alone each year and has a 30-day mortality of 13.8%,[55] is associated with decreased levels
of these protective bacteria.[52, 56] Even more interestingly, C. difficile-negative
nosocomial diarrhea is also associated with a decrease in butyrate-producing bacteria,
suggesting that the overall integrity of the epithelial barrier is dependent on sufficient levels
of butyrate in the intestinal track.[56] In a small study of CD patients, oral butyrate showed
promising results inducing remission and improving symptoms,[57] suggesting that oral
supplementation may be able to overcome the dysbiotic state IBD patients live with.
Choline
Choline is a vital component of cell membranes, typically obtained from red meat and eggs,
but which can also be biosynthesized.[58, 59] It is central to lipid metabolism, and plays a
role in the synthesis of very-low-density lipoprotein (VLDL) in the liver.[58] Recent studies
have implicated deficiencies in choline in the development of non-alcoholic fatty liver
disease (NAFLD) and enhancing progression to non-alcoholic steatohepatitis (NASH).
NAFLD occurs in 20–30% of the general population, while the prevalence in obese patients
is 75–100%.[60, 61] Although patients with NAFLD remain asymptomatic, 20% progress to
NASH, which results in increased mortality through cirrhosis, hepatocellular carcinoma, and
portal hypertension.[62–64]
Mice fed diets deficient in methionine-choline develop a NASH phenotype, and this process
was negatively regulated by the NLRP6 and NLRP3 inflammasomes as well as their effector
protein IL-18.[63] This phenotype was associated with changes in the composition of the gut
microbiota, specifically increased amounts of Erysipelotrichi. The enhanced liver
inflammation seen in the various knockout strains was transmissible to co-housed WT mice.
[63] The enhanced severity in inflammasome-deficient mice was mediated by Toll-like
Receptors 4 and 9 through TNF-α, and enhanced levels of TLR4 and 9 agonists were found
in the portal circulation of inflammasome-defective mice also deficient in choline intake,
likely as a result of sub-clinical colonic inflammation mediated by CCL5.[63] Interestingly,
some of these same observations have been found in human subjects. Patients fed a diet
deficient in choline had increased accumulation of hepatic fat and the most susceptible
patients where those with increased amounts Erysipelotrichi and decreased levels of
Gammaproteobacteria in their stool at baseline.[65]
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The genetic background of mice (including SNPs) is an important sculptor of the gut
microbiota.[58, 66– 68] A comparison study between two inbred mouse strains, one resistant
to NAFLD (BALB/c) and one that is susceptible (129S6) when fed a high fat diet, found that
the susceptible strain had lower levels of plasma phosphatidylcholine and higher levels of
urinary methylamines.[69] These methylamines are produced exclusively by the gut
microbiota as a downstream metabolite of choline. Thus, the microbial composition, as
determined by host genetics (and environment), alter the downstream bioavailability of a
metabolite (choline) with health consequences for the host.[69] A similar effect of genetics
on microbiota was also observed in humans; the PEMT polymorphism increases
susceptibility to NAFLD through decreased phosphatidylcholine synthesis. In humans on a
normal diet, the abnormal PEMT allele was associated with exacerbated NAFLD in patients
with increased stool levels of Erysipelotrichi and decreased levels of Gammaproteobacteria.
[65] Patients with the normal allele but with the NAFLD-prone microbial composition had
lower levels of hepatic steatosis on a normal diet, suggesting that patients with intact
phosphatidylcholine synthesis were able to overcome a NAFLD-inducing gut microbial
composition while patients with the PEMT polymorphism were not.[65]
Interestingly, the aforementioned NLRP6 deficient mice, which show enhanced NASH in
the absence of dietary choline, also develop exacerbated colitis in response to DSS through
increased CCL5 secretion.[70] This phenotype, like that of the NASH model, is also
transmittable through the microbiota to wild-type hosts, as the altered microbiota generated
by the NLRP6−/− intestine are responsible for increased CCL5 secretion.[70] Choline has
not been implicated in this model, however. Additionally, in the murine IL-10−/− model of
spontaneous colitis, which is dependent on the presence of commensal microbiota,[71, 72]
decreased levels of plasma choline were observed, alongside increased choline in
phospholipids typical of inflammatory processes.[73] An increase in the urine concentration
of trimethylamine (TMA), a gut microbial metabolite of choline, was also observed in
IL-10−/− mice, particularly as disease progressed over time,[74] suggesting that the
decreased plasma levels of choline in IL-10−/− mice may be the result of increased microbial
metabolism of dietary choline. Interestingly, deficiencies in choline are also observed in the
colonocytes of patients with active UC when compared to UC patients with quiescent
disease.[75] However, the role of choline deficiency in experimental colitis and human IBD
remains to be determined.
Enteric bacterial metabolism of choline has also been implicated in cardiovascular disease
(CVD) and the generation of atherosclerosis. While it has traditionally been thought that
saturated fats and red meat were associated with an increased risk of CVD, recent meta-
analyses have found no correlation between saturated fat consumption[76] or red meat
consumption[77] and CVD; only processed meats were noted to be correlated.[77] In
humans, three metabolites of phosphatidylcholine: choline, TMA-N-oxide (TMAO), the
human metabolite of bacteria-produced TMA[78]), and betaine, were found to predict CVD
in a cohort study.[79] In Apoe−/− atherosclerosis-prone mice, dietary supplementation with
choline or TMAO promoted atherosclerosis, which was associated with increased plasma
levels of TMAO.[79] These diets were also associated with increased levels of macrophage
foam-cells, and increased amounts of expression of the macrophage scavenger receptors
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CD36 and SR-A1, both of which are implicated in atherosclerosis.[79] Atherosclerosis was
positively correlated with increased plasma levels of TMAO, and increased expression of
the hepatic enzyme FMO3 that converts TMAs to TMAOs.[79] Because choline produces
TMAOs through the bacteria-metabolite intermediate TMAs. The authors hypothesized that
the microbiome played a central role in driving choline-induced atherosclerosis. Not
surprisingly, germ-free mice did not produce increased levels of TMAO when fed a high-
choline diet, and antibiotic decrease of resident bacteria reduced plasma levels of TMAO
and prevented dietary-cholineinduced macrophage foam cell production and atherosclerosis.
[79]
Interestingly, patients with IBD have an increased risk of CVD, despite having a general
lower incidence of traditional risk factors.[80–82] Based on the current literature, microbial
choline metabolism may be the missing link explaining this association. IBD has recently
been associated with high levels of urine TMA, indicating increased choline
metabolism[73–75] and decreased choline bio-availability. Similarly, increased levels of the
downstream metabolite of TMA, TMAO, is associated with increased atherosclerosis.[79]
This suggests that the dysbiosis associated with IBD may define a microbiome that favors
choline metabolism, decreasing choline bioavailability and increasing downstream
atherosclerotic metabolites.
Carnitine
The role of dietary carnitine in the development of atherosclerosis appears very similar to
that of choline. L-carnitine is an abundant nutrient in red meat, which like choline, is
processed by the enteric microbiota into TMAs.[83, 84] In a recent study using the same
metabolomics data set analyzed in the choline study,[79] plasma levels of L-carnitine were
also associated with CVD.[83] Using a radio-labeled L-carnitine challenge test, Koeth, et al
found that broad spectrum antibiotics diminished the metabolic conversion of L-carnitine to
the pro-atherosclerotic metabolite TMAO,[83] indicating a vital role for the microbiome in
carnitine-associated atherosclerosis. Furthermore, they found that vegans and vegetarians
had lower levels of plasma carnitine and a markedly reduced capacity to synthesize TMAO
after a carnitine challenge. These differences in ability to metabolize L-carnitine, as
measured by TMAO levels, were associated with several microbial taxa. Additionally, using
the aforementioned enterotype classification,[6] the Prevotella enterotype was associated
with higher plasma levels of TMAO than the Bacteroides enterotype.[83] Germ-free and
antibiotic administration studies in mice confirmed that intestinal microbial metabolism of
carnitine to TMA is central to carnitine-enhanced atherosclerosis, and follow-up studies in
an independent cohort of human patients found a dose-dependent relationship between
plasma carnitine levels and CVD.[83] Mechanistically, increased levels of TMAOs were
associated with decreased levels of reverse cholesterol transport, through alterations at
multiple sites of the bile acid synthetic pathway.[79, 83]
Dietary and Supplemental Iron
Iron supplementation serves as a prototypical example of the newly discovered complex
interactions between diet, the host immune system, and the gut microbiome, which has
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downstream consequences for gut homeostasis and health. Iron deficiency is the most
common cause of anemia worldwide, and oral iron supplementation is commonly prescribed
for patients diagnosed with anemia[85]. Many patients with IBD suffer iron deficiency
anemia, in addition to frequent anemia of chronic disease, and are consequently given oral
and/or parenteral iron supplementation as part of their treatment course[86, 87]. Clinically, it
has long been observed that oral iron supplementation is poorly tolerated by some IBD
patients, and anecdotally there were some concerns that symptoms of IBD patients worsened
while on oral iron therapy.[88, 89] Iron is a known pro-oxidative agent, raising concern that
oral iron may increase oxidative stress in patients with colitis as a mechanism of
exacerbating disease[90].
Because of these concerns, rodent studies examined the interplay between intestinal
inflammation and iron supplementation. Initial studies in both an iodoacetamide rat model of
colitis[90] and in a DSS murine model of colitis [91] demonstrated that oral ferrous sulfate
administration exacerbated disease. Initial mechanistic studies suggested that iron
supplementation increased tissue oxidative stress[90], perhaps through increased tissue iron
deposition.[91] Follow-up in vitro studies in a human colonic tumor cell line supported the
hypothesis that iron supplementation enhanced reactive oxygen species (ROS) formation,
which could lead to increased tissue damage[92]. Proteomic analysis of the effects of iron
supplementation in the TNFΔARE/WT model of spontaneous, chronic ileitis (driven by
overproduction of TNF) demonstrated that iron supplementation exacerbated disease
through contrarily regulated proteins involved in energy homeostasis, host defense, and
oxidative and endoplasmic reticulum (ER) stress responses.[67] These proteins were
aconitase 2, catalase, intelectin 1, and fumarylacetoacetate hydrolase (FAH).[67]
Dysfunction of the unfolded protein response (UPR) and downstream autophagic processes
as a result of ER stress has been implicated in the pathogenesis of human IBD.[93]
Dysfunction of XBP1 protein in mice[94], as well as the downstream UPR effector ATF6 in
both mice[95] and zebrafish[96], appear to be involved the pathogenesis of colitis. One of
the key drivers of ER stress in enterocytes is bacterial signaling and translocation across the
epithelial barrier [97]. The IBD-susceptibility gene ATG16L1 in combination with murine
norovirus infection has been reported to alter Paneth cell function, and is also important for
autophagy, the primary response to ER stress[98]. Paneth cells generate numerous
antimicrobial peptides and are fundamental to shaping the gut microbial environment.[97]
Similarly, NOD2, an intracellular bacterial sensor protein, is also a known IBD-
susceptibility gene, with dysfunctional mutations leading to defects in autophagy and
resulting intestinal inflammation.[97, 99, 100] Interestingly, oral iron seems to alter these
same ER stress/UPR pathways found to be critical in IBD pathogenesis. In the TNFΔARE/WT
model of chronic ileitis, oral, but not parental iron, exacerbated disease and enhanced
downstream UPR and apoptotic signaling.[101] While oral iron deprivation did not alter T-
cell numbers or function, it appeared to sensitize epithelial cells to T-cell (CD8αβ+)-induced
apoptosis.[101] Additionally, the lack of oral iron intake in mice altered the microbial
composition of both WT and TNFΔARE/WT mice in a similar fashion, independent of the
presence of inflammation.[101] Interestingly, while composition was altered, the lack of oral
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iron intake did not result in changes to overall microbial diversity as measured by the
Shannon’s diversity index, nor the number of total operational taxonomic units.[101]
Together, these studies suggest that oral iron intake alters gut microbial composition and
perhaps function. These alterations either alone or in parallel with direct induction of ROS
by iron lead to increased cell stress in enterocytes with subsequent sensitization to
inflammatory damage. Thus, during an acute IBD flare, additional of oral iron, which is
commonly prescribed today, may actually exacerbate disease. Based on this body of work,
parental iron should be considered for actively flaring IBD patients, with oral
supplementation (which is slow to replete iron reserves in any case) used when a patient’s
disease is quiescent.
Fat
A landmark study recently evaluated the influence of milk fat on the microbiome in murine
colitis. Wildtype mice fed a high fat diet comprised of either saturated milk fat (MF diet) or
polyunsaturated safflower-oil fat (PUFA diet) had higher abundances of the Bacteroidetes
phylum and decreased levels of Firmicutes, while mice fed a low-fat diet (LF diet) showed
the opposite pattern.[102] This pattern mirrored that of the enterotypes seen in human
dietary studies.[8] Interestingly, in both the IL-10−/− and DSS models of colitis, the MF diet,
but not the PUFA diet, exacerbated disease.[102] This was associated with an increase in
Bilophila wadsworthia, a sulfite-reducing bacteria that produces H2S, a substance known to
drive T-cell activation and increase gut permeability, and which has been implicated as a
bacterial toxin in UC.[102–104] In this work, mono-association studies with germ-free mice
demonstrated that milk-fat was needed to support colonization of B. wadsworthia, and that
this specific bacteria was colitogenic, through induction of a TH1 immune response
involving IFNγ and IL12 production.[102] Production of taurine-conjugated bile acids
(taurocholic acids), a preferred fuel source of B. wadsworthia[105], is driven by the
consumption of hydrophobic fats such as present in the MF diet,[106] and was found to be
the key metabolite supporting the bloom of B. wadsworthia in these studies.[102] This study
may explain some of the observations in the 1960s that milk consumption was inversely
correlated with in disease activity in UC patients[107] and increased milk-protein
antibodies,[108] but that follow-up studies exploring the presence of milk allergy as an
etiology for IBD were largely negative.[109] Additionally, B. wadsworthia levels were
increased in the animal-based short-term diet study,[10] providing evidence that high-fat
diets can induce similar changes in microbial changes in humans to those seen in mice.
However, the pathogenicity of B. wadsworthia in human IBD remains to be explored.
Not all fat is harmful, however. In mice n-3 poly-unsaturated fatty acids (PUFAS,
commonly known as omega-3 fatty acids) enhance 5-ASA-mediated recovery from TNBS-
colitis[110], reduce obesityassociated Th17 inflammation during TNBS-colitis[111], reduce
cytokine production and disease severity in T-cell transfer colitis[112], and reduce Th17 cell
populations and disease severity in DSS colitis.[113] In contrast, trans-fats appear to
exacerbate DSS colitis through up-regulation of Th17 signaling.[114] Unfortunately, the
results in human CD patients have been more mixed, with conflicting studies finding that
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omega-3 fatty acids either decreased the rate of relapse,[115] or had no effect on the
remission rate[116].
Clinical Implications
The hope of impacting health through diet may be one of the oldest concepts in medicine;
however, only in recent years has our understanding of human physiology grown to the
point where we can begin to understand how individual dietary components affect specific
illnesses (Figure 1). In particular we have begun to understand how the host microbiome,
often through complex interplays with the immune system, serves as a central mediating
axis in this process. The data presented in this review have important potential clinical
implications (Figure 1), although more work needs to be done to fully validate the following
conclusions and to fully develop potential therapeutic approaches.
IBD patients frequently identify dietary components as triggers of increased symptoms and
therefore may adopt rather rigid dietary preferences based on their individual experiences.
[117] These empiric observations, however, are unique to individuals and need to be more
thoroughly investigated by integrated studies of the intestinal microbiome, metagenome, and
metabolome. Significant mechanistic advances have been made regarding iron[67, 90, 91,
101] and milk fat[102] in animal models of colitis and ileitis, providing for the first time
experimental evidence to back up long-discussed anecdotal observations of diet and IBD.
Many IBD patients empirically adopt dairy- free diets,[117] but it is not clear whether this is
due to lactose deficiency, milk protein allergy, or intolerance of other milk components. A
new insight is provided by the observation that milk fat can induce colitis in genetically
susceptible IL-10 deficient mice by selectively altering bile acid profiles and stimulating
expansion of a rare anaerobic bacteria, B. wadsworthia.[102] Future studies should target
these bile acid and bacterial profiles in human studies, particularly comparing milk- tolerant
and intolerant IBD patients. Oral iron can be inflammatory at doses relevant to Western diets
and supplements prescribed to patients.[67, 90, 91, 101] Many IBD patients are anemic and
are given therapeutic iron, often during a flare, with improved quality of life after improving
hemoglobin levels.[118] Although some clinical studies indicate better clinical tolerance
with intravenous compared to oral iron supplementation,[88] this is not universally
supported[87] and the majority of clinicians continue to use oral iron supplementation,
although the use of IV iron therapy is increasing in some but not all locations.[119, 120]
This important clinical issue needs to be resolved with a more comprehensive analysis of the
microbiome and fecal metabolome in those patients tolerant vs. intolerant to oral iron
therapy to determine a predictive model of optimal supplementation.
IBD patients also frequently include red meats on their list of food intolerances.[117]
Whether this perceived intolerance is due to the presence of fats, iron, L-carnitine or other
components is unknown. The microbiome-metabolite TMA, which appears to drive diverse
inflammatory pathologies, ranging from IBD[73–75] to atherosclerosis,[79, 83] through the
host-produced TMA metabolite TMAO. Dietary consumption of phosphatidylcholine and L-
carnitine provide substrates for resident enteric bacterial metabolism to TMA, which is then
converted in the liver to TMAO. The processes involved in establishing and maintaining a
high-TMA-producing microbiome remain to be determined, but host genetics appear to be a
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contributing factor.[75, 79, 83] Elegant animal and human studies have defined this pathway
in atherosclerosis. [79, 83] Further studies should target specific microbial targets to block
this metabolic conversion, in parallel with dietary intervention studies. Outside of
atherosclerosis and IBD, selective choline supplementation may be helpful in patients with
NAFLD/NASH. Similarly, once more is understood about the specific microbes that convert
choline/carnitine into TMA, targeted antibiotic therapy could be used to decrease these
organisms. Doing so would help to both prevent NAFLD/NASH and the atherosclerosis
resulting from UC dysbiosis; as the liver would receive more beneficial dietary choline
while simultaneously decreasing the production of atherosclerotic TMA.
While TMA is an example of a harmful bacterial metabolite, other protective metabolites
produced by a subset of enteric microbiota, including groups IV and XIVA Clostridium
species and F. prausnitzii,[49, 52, 53, 56], are reproducibly decreased in IBD and many
other inflammatory disorders, and serve as potential therapeutic candidates. These bacteria
metabolize nondigestible dietary carbohydrate (fibers, prebiotics) to SCFAs. SCFAs, in
particular butyrate, have multifaceted protective properties that include inhibiting
proinflammatory cytokines through HDAC activity, inducing regulatory Treg, and
stimulating colonic epithelial restitution.[23, 25, 28, 30–35, 41, 45–50, 52–54, 57] The
volatility and instability of SCFAs limit their direct therapeutic application. However,
indirect approaches such as restoring luminal concentrations and biologic activity of
protective bacterial subsets by novel probiotics using depleted resident species [17, 48] and
dietary substrates such as prebiotics and fiber have considerable nontoxic, physiology
potential. In addition there are other factors, such as omega-3 fatty acids,[111–113] retinoic
acid, vitamins A, C, D, and E, which function independent of the microbiome and show
some therapeutic benefits, and which could be used as an adjunctive anti-inflammatory
agent in patients with IBD and atherosclerosis.
Additional areas of very active and productive clinical investigation are interactions between
diet and the microbiome in obesity, Type 2 diabetes, and metabolic syndrome.[1, 12]
Obesity is clearly associated with abnormal microbial profiles,[10–14] but results are
somewhat inconsistent regarding discrete profiles. For example, one study reported that
Bacteroides was negatively associated with obesity,[14] while another study found the
opposite trend.[16] Amounts of the protective bacteria F. prausnitzii[17] were found to be
negatively correlated with both IBD[16] and obesity.[16] Together, these works suggest that
a pro-inflammatory profile of bacteria predisposes the host to a variety of metabolic and
inflammatory processes. However, ambiguity still persists regarding whether a given
dysbiosis is merely correlative or an actual causative factor in obesity, particularly regarding
the role of Bacteroides in obesity.[8, 14, 16] This may be in part due to the role that nutrient
influx plays in shaping a microbiome,[15] which varies between obese and lean individuals.
Of note, these trends also appear among the elderly, with more the frail elderly having less
diverse microbiomes, decreased numbers of SCFA producers and increased levels of
inflammatory markers such as CRP and IL-6,.[121] Interestingly, in the elderly, the same
trends also appeared when the patients were analyzed by diet, suggesting that changes in
nutritional input may be generating the microbial changes, with subsequent downstream
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health impacts.[121] These observations imply that diet and nutritional status may be a key
intervention to help the elderly.
Overall, the microbiome field has undergone a massive revolution in the last decade, with
the availability of affordable microbiome-wide genetic sequencing and the expansion of
germ-free and gnotobiotic mouse technologies. As we begin to identify the factors that lead
to the development of bacterial community structure and function and learn how these
microbiota and their metabolism of dietary components shape human health and disease,
completely new types of physiologic, nontoxic therapies could develop, focusing on
sculpting the diet and microbiome to promote health.
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Figure 1. The complex interplay of dietary elements, the microbiota, and the host can be
beneficial or detrimental to host health
Milk fat (blue): increased consumption of milk fat leads to increased levels of taurine-
conjugated bile acids, which result in a bloom of Bilophila wadsworthia, a colitogenic
H2Sproducing bacteria. Fiber (pink): Consumption of fiber leads to the production of
butyrate and other short-chain fatty acids by colonic bacteria. These SCFAs promote
epithelial healing and decrease intestinal inflammation, in part through induction of Tregs.
Choline/carnitine (green): Dysbiotic states, as found naturally in a subset of patients or in
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patients with IBD, results in the increased bacterial metabolism of choline and/or carnitine
to TMA. This decreases the bioavailability of choline, leading to NAFLD/NASH, while
increased levels of TMA are metabolized by the liver to TMAO, an atherosclerotic
compound. Iron (black): Increased oral iron intake is associated with increased intestinal
epithelial cell stress and cell death and altered microbiota profiles, which may exacerbate
active IBD.
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Table 1
The role of various dietary elements on the pathogenesis of gastrointestinal illnesses
Disease Dietary Item Key Findings Key References
IBD Iron Oral, but not parental, iron exacerbates experimental colitis. Results
in human IBD are controversial, but IV iron may be more easily
tolerated
[67, 87, 88, 90, 91, 101,
118–120]
SCFA Lack of SCFA-producing bacteria is associated with IBD, and
butyrate supplementation, replacement of selected bacteria or feeding
prebiotics offer potential treatments
[23, 25, 28, 30–35, 41, 45–
50, 52–54, 57]
Choline Experimental murine colitis and human UC patients have decreased
levels of serum choline and increased levels bacterial products of
choline metabolism.
[73–75]
Milk Fat Milk fat promotes a bloom of the colitogenic bacteria Bilophila
wadsworthia in experimental murine colitis through increased levels
of taurocholic acid.
[102]
Omega-3 fatty acids Reduce Th17-mediated inflammation and disease severity in multiple
murine models of colitis. Inconsistent results in human IBD studies.
[110–113, 115, 116]
IBS Fermentable sugars A diet low in fermentable oligosaccharides, disaccharides,
monosaccharides, and polyols (FODMAP) reduced IBS symptoms.
[122]
Gluten Gluten alters barrier function in IBS-D patients, particularly those
with HLA-DQ2/8 immune-typing, leading to worse symptoms.
[123]
NAFLD/NASH Choline Dietary choline deficiency predisposes patients to NAFLD/NASH,
particularly in those patients with mutations affecting endogenous
phosphatidylcholine synthesis or with microbiomes with excessive
metabolic breakdown of choline
[58, 65, 69, 74]
CVD TMA-precursors Choline and carnitine are both metabolized by the microbiome to
TMA, which is metabolized by the host to atherosclerosis-promoting
TMAO.
[79, 83]
Diverticulosis Fiber A high-fiber diet is not protective against asymptomatic
diverticulosis
[124]
Alcohol Alcohol is a risk factor for chronic diverticulosis, with increasing
consumption enhancing risk
[125]
Celiac Disease Gluten Celiac’s disease is widely known to be caused by an immune
intolerance to gluten, which occurs in a genetically susceptible host.
[126]
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